Which vaccines are recommended for a healthy 50-year-old adult?

Recommended Vaccines at Age 50

At age 50, a healthy adult should receive annual influenza vaccine, Tdap (if not previously received) followed by Td boosters every 10 years, and consider starting the recombinant zoster vaccine (Shingrix) series, though official ACIP recommendations begin at age 60. 1

Core Vaccines for 50-Year-Olds

Annual Vaccines

• Influenza: Administer annually with inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). Live attenuated influenza vaccine (LAIV) is also an option for this age group 1

Tetanus, Diphtheria, and Pertussis

• Tdap: One dose if not previously received as an adult, then Td or Tdap booster every 10 years 1
• This protects against pertussis (whooping cough), which adults can transmit to vulnerable populations

Zoster (Shingles) Vaccine

• Recombinant zoster vaccine (RZV/Shingrix): While the 2020 ACIP schedule shows this beginning at age 65 1, more recent guidelines from 2019 indicate it can be given starting at age 50 2
• Two-dose series administered 2-6 months apart (minimum interval 4 weeks) 2
• This is the preferred vaccine over the older live zoster vaccine (ZVL)

Pneumococcal Vaccination Considerations

For healthy 50-year-olds without risk factors, pneumococcal vaccination is NOT routinely recommended until age 65. However, the 2025 guidelines indicate pneumococcal vaccination should be considered starting at age 50 3. The most recent evidence suggests:

• PCV20 or PCV15/PCV21: Recommended starting at age 50 if never previously vaccinated with a pneumococcal conjugate vaccine 3
• For those aged 50-64 with chronic conditions (heart disease, lung disease, liver disease, diabetes), alcoholism, or cigarette smoking: one dose of PPSV23 is recommended 1

Catch-Up Vaccinations to Verify

MMR (Measles, Mumps, Rubella)

• If born in 1957 or later and lacking documentation of vaccination or immunity: 1-2 doses depending on risk factors 1
• Healthcare workers and international travelers need 2 doses

Varicella (Chickenpox)

• If born in 1980 or later without evidence of immunity: 2-dose series 1
• Evidence of immunity includes: documented 2-dose vaccination series, U.S.-born before 1980 (except healthcare personnel), history of varicella or herpes zoster diagnosed by a provider, or laboratory evidence of immunity

Hepatitis B

• Universal recommendation for adults aged 19-59 years per 2023 guidelines 4
• HEPLISAV-B: 2-dose series at 0 and 1 month (preferred for faster completion)
• Alternative: 3-dose series with Engerix-B, Recombivax HB, or PreHevbrio at 0,1, and 6 months 5

HPV (Human Papillomavirus)

• Not routinely recommended at age 50
• Standard recommendation is through age 26; may be given ages 27-45 based on shared clinical decision-making 1

COVID-19 Vaccination

• Follow current ACIP recommendations: 1 or more doses of updated vaccine for adults aged 19-64 years 3
• Stay current with updated formulations as they become available

Special Considerations and Common Pitfalls

Risk-Based Vaccinations

If you have specific risk factors, additional vaccines may be indicated:

• Hepatitis A: For chronic liver disease, travel to endemic areas, men who have sex with men, injection drug use
• Meningococcal: For asplenia, complement deficiencies, travel to endemic areas
• Haemophilus influenzae type b: For asplenia or immunocompromising conditions

Timing Considerations

• Do not delay routine vaccines even if you're behind schedule—catch-up vaccination is appropriate at any age 1
• Vaccines can generally be administered simultaneously at different anatomic sites
• If you're planning international travel, consult travel medicine recommendations 4-6 weeks before departure

Documentation

• Maintain a personal immunization record
• Self-report of previous doses is acceptable for some vaccines like polio 3
• If vaccination history is uncertain and no records exist, revaccination is generally safe and preferred over serologic testing for most vaccines

Critical Action Point

The single most important vaccine at age 50 is annual influenza vaccination, as influenza causes significant morbidity and mortality in adults and vaccination reduces both disease burden and transmission to vulnerable populations. The second priority is ensuring Tdap has been received (if not already done), followed by consideration of starting the shingles vaccine series, particularly given the 2-dose series can be completed before age 60 when risk of herpes zoster increases substantially.